Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 3Myeloid 2Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 91Myelodysplastic Syndromes 26Leukemia, Myelomonocytic, Chronic 12Myeloproliferative Disorders 8Leukemia 6Hematologic Neoplasms 5Recurrence 4Leukemia, Biphenotypic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Hematologic Diseases 3Anemia, Refractory, with Excess of Blasts 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycythemia Vera 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell 2Leukemia, Neutrophilic, Chronic 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Immunoblastic Lymphadenopathy 2Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma, Myeloid 1Pathologic Complete Response 1Neurofibromatosis 1 1Neoplasm Metastasis 1

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Azacitidine × 90 days × Clear all
NCT05829226 2026-05-06

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

PureTech

Phase 1 Completed
101 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04588922 2026-05-01

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Sellas Life Sciences Group

Phase 1/2 Recruiting
160 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡